About Idorsia Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland...
Conference call participants should start calling the number below 10-15 minutes before the conference is due to start. Dial-in: CH: +41 (0)44 580 71 45 | UK: +44 (0) 2071 928338| US: +1 646 741 3167 PIN:4838017 About Idorsia Idorsia Ltd is reaching out for more – We have mor...
Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12receptor antagonist, in suspected acute myocardial infarction (AMI). An AMI, or heart attack, is...